Product
IBI302
Aliases
dose 1 IBI302, dose 2 IBI302
3 clinical trials
2 indications
Indication
Age-Related Macular DegenerationIndication
Diabetic Macular EdemaClinical trial
A Multi-center, Randomized, Double-masked, Active-controlled Study to Evaluate the Longer Interval of Intravitreal (IVT) Injection of IBI302 in Subjects With Neovascular Age-related Macular Degeneration (nAMD)Status: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Phase 3, Randomized, Double-masked, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravitreal IBI302(Efdamrofusp Alfa) in Subjects With Neovascular Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2027-02-28
Clinical trial
A Dose Escalation Study to Evaluate the Safety and Tolerability of IBI302 Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema AND A Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With Diabetic Macular EdemaStatus: , Estimated PCD: 2023-10-31